Azymus Therapeutics, an emerging pharmaceutical company, is advancing 10-years of nano-therapeutic research supported by its flagship AZ Platform. The company is studying applications of next-generation therapies in neurodegenerative diseases and chemo-resistant cancers. Azymus is partnering with universities, researchers, pharmaceutical companies, and investors to advance its treatments.
"Azymus Therapeutics is developing solutions for diseases that currently lack effective treatments. That's been our team's pursuit for the better part of a decade," said Christopher D. Jones, chief executive officer of Azymus Therapeutics. "Our AZ Platform is positioned to advance interventions for diseases like Parkinson's and treatments for chemo-resistant cancers."
Leveraging its precision nanotechnology, Azymus generates tailored microvesicular particles to deliver optimized concentrations of specific proteins and genetic materials for therapeutic interventions, or living drugs. Living drugs eliminate systemic toxicity associated with synthetic or semi-synthetic molecules used in non-targeted therapy.
The AZ Platform enables researchers to discover ways to influence microvesicular composition to impact the disease state in Parkinson's and chemo-resistant cancers. Azymus's proof-of-concept (PoC) studies on drug candidates AZ001 and AZ002 revealed the role of reactive oxygen species (ROS) metabolism and mitochondrial bioenergetics as cellular mechanisms for evading cell death.
Azymus is currently conducting a preclinical study focusing on the use of biologics for neuronal regeneration and slowing down the progression of Parkinson's disease. PoC studies have provided mechanistic insights into how living drugs may restore the neuronal circuitry that affects motor functions and improve quality of life for Parkinson's patients.
